Short Interest in Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Decreases By 25.6%

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLYGet Free Report) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 30,200 shares, a drop of 25.6% from the February 13th total of 40,600 shares. Based on an average trading volume of 765,800 shares, the short-interest ratio is currently 0.0 days.

Ono Pharmaceutical Trading Up 0.0 %

Shares of Ono Pharmaceutical stock traded up $0.00 during midday trading on Monday, hitting $3.68. The company had a trading volume of 205,942 shares, compared to its average volume of 458,863. The business’s 50 day simple moving average is $3.46 and its two-hundred day simple moving average is $3.88. Ono Pharmaceutical has a 1-year low of $3.21 and a 1-year high of $5.67.

Ono Pharmaceutical Company Profile

(Get Free Report)

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.

See Also

Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.